MedTrace Logo

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2018-07-17

Study results available
· View outcomes & findings →

Summary

This is a long term, open-label, safety extension study in subjects with partial onset seizures.

Conditions

Interventions

DRUG

Eslicarbazepine acetate

800 to 2400 mg once daily (QD)

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • CNS Medical Director · Sunovion Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2017-04-15
Completion
2017-04-15

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910247 on ClinicalTrials.gov